Count Re­gen­eron as the lat­est big bio­phar­ma com­pa­ny to pitch in on find­ing a ther­a­py to com­bat the Wuhan virus.

A bill that re­quires the Di­rec­tor of Na­tion­al In­tel­li­gence to de­clas­si­fy new in­for­ma­tion on the ori­gins of Covid-19 passed the House … ...

Long af­ter many an­a­lysts had giv­en Mer­ck’s CETP heart drug anace­trapib up for dead fol­low­ing a slate of ex­pen­sive buri­als for the first three drugs … ...

As Re­gen­eron moves its an­ti­body cock­tail in­to Phase II/III tri­als test­ing REGN-COV2 as a treat­ment for both hos­pi­tal­ized and non-hos­pi­tal­ized pa­tients with Covid-19, the … ...

If any­one wants a les­son in the val­ue of be­ing first-in-class and best-in-class in the drug busi­ness, pick up a copy of Pfiz­er’s quar­ter­ly re­port … ...

Af­ter Pfiz­er and BioN­Tech scored the FDA’s emer­gency use au­tho­riza­tion for their mR­NA-based Covid-19 shot late last week, hopes are high that one or … ...

Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

LON­DON — With a loom­ing ex­it from the EU com­ing up, it’s not hard for any com­pa­ny to spur in­tense anx­i­ety in the UK … ...

Back in the sum­mer of 2019, Carl Hansen left his post as a pro­fes­sor at the Uni­ver­si­ty of British Co­lum­bia to go full time as … ...

When Pres­i­dent Joe Biden’s bud­get comes out on Thurs­day, ex­pect to see a big, po­ten­tial­ly mul­ti-bil­lion-dol­lar pro­pos­al to re­al­ly take a crack at cur­ing more … ...

De­spite Ugur Sahin’s calls for calm over the Omi­cron vari­ant — mak­ing a much more mea­sured ap­peal than Mod­er­na CEO Stéphane Ban­cel — the BioN­Tech chief is … ...